Advertisement
Research Article

The Alzheimer's Disease-Associated Amyloid β-Protein Is an Antimicrobial Peptide

  • Stephanie J. Soscia,

    Affiliations: Genetics and Aging Research Unit, Mass General Institute for Neurodegenerative Disease and Department of Neurology, Massachusetts General Hospital, Charlestown, Massachusetts, United States of America, Department of Anatomy and Neurobiology, Boston University School of Medicine, Boston, Massachusetts, United States of America

    X
  • James E. Kirby,

    Affiliation: Department of Pathology, Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States of America

    X
  • Kevin J. Washicosky,

    Affiliation: Genetics and Aging Research Unit, Mass General Institute for Neurodegenerative Disease and Department of Neurology, Massachusetts General Hospital, Charlestown, Massachusetts, United States of America

    X
  • Stephanie M. Tucker,

    Affiliation: Genetics and Aging Research Unit, Mass General Institute for Neurodegenerative Disease and Department of Neurology, Massachusetts General Hospital, Charlestown, Massachusetts, United States of America

    X
  • Martin Ingelsson,

    Affiliation: Department of Public Health/Geriatrics, Uppsala University, Uppsala, Sweden

    X
  • Bradley Hyman,

    Affiliations: Genetics and Aging Research Unit, Mass General Institute for Neurodegenerative Disease and Department of Neurology, Massachusetts General Hospital, Charlestown, Massachusetts, United States of America, Harvard Medical School, Boston, Massachusetts, United States of America

    X
  • Mark A. Burton,

    Affiliations: Molecular Aging and Developmental Laboratory, Photonics Center, College of Engineering, Boston University School of Medicine, Boston University, Boston, Massachusetts, United States of America, Boston University Alzheimer's Disease Center, Boston University, Boston, Massachusetts, United States of America

    X
  • Lee E. Goldstein,

    Affiliations: Molecular Aging and Developmental Laboratory, Photonics Center, College of Engineering, Boston University School of Medicine, Boston University, Boston, Massachusetts, United States of America, Boston University Alzheimer's Disease Center, Boston University, Boston, Massachusetts, United States of America

    X
  • Scott Duong,

    Affiliation: Department of Pathology, Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States of America

    X
  • Rudolph E. Tanzi mail,

    tanzi@helix.mgh.harvard.edu

    Affiliations: Genetics and Aging Research Unit, Mass General Institute for Neurodegenerative Disease and Department of Neurology, Massachusetts General Hospital, Charlestown, Massachusetts, United States of America, Harvard Medical School, Boston, Massachusetts, United States of America

    X
  • Robert D. Moir

    Affiliations: Genetics and Aging Research Unit, Mass General Institute for Neurodegenerative Disease and Department of Neurology, Massachusetts General Hospital, Charlestown, Massachusetts, United States of America, Harvard Medical School, Boston, Massachusetts, United States of America

    X
  • Published: March 03, 2010
  • DOI: 10.1371/journal.pone.0009505

Reader Comments (7)

Post a new comment on this article

The Alzheimer's Disease-Associated Amyloid β-Protein Is an Antimicrobial Peptide

Posted by ruthitzhaki on 12 Mar 2010 at 15:46 GMT

In 2004, Bishop and Robinson [1] hypothesised that one function of β-amyloid (Aβ) might be to protect against pathogens and now Soscia et al. present convincing experimental data for a role of Aβ as an antimicrobial peptide that may normally function in the innate immune response [2]. These results might explain why several micro-organisms lead to Aβ accumulation in cell culture and/or in mouse models. Chlamydia pneumonia and Borrelia burgdorferi spirochetes have been detected in a high proportion of Alzheimer’s disease (AD) brains [3,4], and both can cause AD-like changes [5,6]. Similarly, herpes simplex virus type 1 (HSV1), which is a risk for AD when present in the brains of APOE-ε4 carriers [7], leads to AD-like changes in cell cultures and mouse brains [8,9], and significantly, viral DNA is very specifically located in AD amyloid plaques [10] (throughout the plaque, not just on the “sticky” surface, as shown in sections that are much thinner than the average plaque diameter). Tests of Aβ’s antimicrobial action against these micro-organisms, as they are directly implicated in AD, would be of particular interest. A significant proportion of antimicrobial peptides show activity against viruses, though this is difficult to predict from sequence alone [11]. One practical difficulty of testing antiviral activity is that any apparent decline in infection due to interference with viral replication must be distinguished from effects on the mammalian cells hosting the viral infection – a particular difficulty for cytotoxic agents like Aβ, as we reported previously [9].

The findings of Soscia et al. may also impact our previously reported observations that the receptor binding region of human apolipoprotein E – the protein coded by APOE, the type 4 allele of which is a major genetic susceptibility factor for AD – has broad antibacterial and antiviral activity [12], and can be utilised to generate a family of broadly acting potent antimicrobial peptides [13]. It would be interesting to examine whether Aβ and apoE demonstrate additive and/or complimentary antimicrobial activities.

The reason why the micro-organisms cause Aβ accumulation is unknown and in the case of HSV1 it seems paradoxical, as the virus decreases the synthesis of most host cell proteins. One possible explanation for the increase in Aβ might be that it is required for the synthesis of progeny micro-organisms, and in fact Aβ fibrils enhance infection of several enveloped viruses, including HSV1 [14]. Alternatively, cells might increase Aβ as part of their defence response, with Aβ possibly acting as an antimicrobial peptide, as Soscia et al. suggest. This is supported by data showing that HIV [15], HSV2 (unpublished observations), and the bacteria mentioned above, and also chemicals (such as hydrogen peroxide [16] and mercury [17]), increase Aβ production. Aβ might initially entomb the agent (at least in the case of pathogens), as implied by Bishop and Robinson [1], thereby preventing further damage to the host, but eventually, through over-production, resulting in toxicity via oligomer formation. However, our investigations into the effect of Aβ on HSV1 revealed that it does not have antiviral activity under the conditions of our experiments, perhaps arguing against a direct defence role for Aβ against HSV1 [9]. Nonetheless in vitro tests of Aβ for antiviral or antibacterial activity might depend on its conformation or extent of aggregation, and therefore it would important to test the antiviral activity of Aβ as prepared in the Socia et al study.

Ruth F Itzhaki, Curtis B Dobson, Matthew A Wozniak

References
1. Bishop GM, Robinson SR (2004) Physiological roles of amyloid-beta and implications for its removal in Alzheimer's disease. Drugs Aging 21: 621-630.
2. Soscia SJ, Kirby JE, Washicosky KJ, Tucker SM, Ingelsson M, et al. (2010) The Alzheimer's Disease-Associated Amyloid beta-Protein Is an Antimicrobial Peptide. PLoS One 5: e9505.
3. Balin BJ, Gerard HC, Arking EJ, Appelt DM, Branigan PJ, et al. (1998) Identification and localization of Chlamydia pneumoniae in the Alzheimer's brain. Med Microbiol Immunol (Berl) 187: 23-42.
4. Miklossy J (1993) Alzheimer's disease--a spirochetosis? Neuroreport 4: 841-848.
5. Little CS, Hammond CJ, MacIntyre A, Balin BJ, Appelt DM (2004) Chlamydia pneumoniae induces Alzheimer-like amyloid plaques in brains of BALB/c mice. Neurobiol Aging 25: 419-429.
6. Miklossy J, Kis A, Radenovic A, Miller L, Forro L, et al. (2006) Beta-amyloid deposition and Alzheimer's type changes induced by Borrelia spirochetes. Neurobiol Aging 27: 228-236.
7. Itzhaki RF, Lin WR, Shang D, Wilcock GK, Faragher B, et al. (1997) Herpes simplex virus type 1 in brain and risk of Alzheimer's disease. Lancet 349: 241-244.
8. Wozniak MA, Frost AL, Itzhaki RF (2009) Alzheimer's disease-specific tau phosphorylation is induced by herpes simplex virus type 1. J Alzheimers Dis 16: 341-350.
9. Wozniak MA, Itzhaki RF, Shipley SJ, Dobson CB (2007) Herpes simplex virus infection causes cellular beta-amyloid accumulation and secretase upregulation. Neurosci Lett 429: 95-100.
10. Wozniak MA, Mee AP, Itzhaki RF (2009) Herpes simplex virus type 1 DNA is located within Alzheimer's disease amyloid plaques. J Pathol 217: 131-138.
11. Jenssen H, Hamill P, Hancock RE (2006) Peptide antimicrobial agents. Clin Microbiol Rev 19: 491-511.
12. Dobson CB, Sales SD, Hoggard P, Wozniak MA, Crutcher KA (2006) The receptor-binding region of human apolipoprotein E has direct anti-infective activity. J Infect Dis 193: 442-450.
13. Kelly BA, Neil SJ, McKnight A, Santos JM, Sinnis P, et al. (2007) Apolipoprotein E-derived antimicrobial peptide analogues with altered membrane affinity and increased potency and breadth of activity. FEBS J 274: 4511-4525.
14. Wojtowicz WM, Farzan M, Joyal JL, Carter K, Babcock GJ, et al. (2002) Stimulation of enveloped virus infection by beta-amyloid fibrils. J Biol Chem 277: 35019-35024.
15. Esiri MM, Biddolph SC, Morris CS (1998) Prevalence of Alzheimer plaques in AIDS. J Neurol Neurosurg Psychiatry 65: 29-33.
16. Olivieri G, Baysang G, Meier F, Muller-Spahn F, Stahelin HB, et al. (2001) N-acetyl-L-cysteine protects SHSY5Y neuroblastoma cells from oxidative stress and cell cytotoxicity: effects on beta-amyloid secretion and tau phosphorylation. J Neurochem 76: 224-233.
17. Olivieri G, Brack C, Muller-Spahn F, Stahelin HB, Herrmann M, et al. (2000) Mercury induces cell cytotoxicity and oxidative stress and increases beta-amyloid secretion and tau phosphorylation in SHSY5Y neuroblastoma cells. J Neurochem 74: 231-236.



No competing interests declared.